June 5, 2019, CHICAGO – The American Academy of Pain Medicine Board of Directors (AAPM) enthusiastically endorses the HHS Pain Management Best Practices Inter-Agency Task Force Final Report, which calls for a balanced, individualized, patient-centered [...]
AAPM 2020: Innovation & Technology in Pain Medicine Meeting Information The AAPM 36th Annual Meeting & Preconferences was held in National Harbor, MD, February 26-March 1, 2020. Thanks to all who participated. View detailed information about [...]
Some combination of data and machinery may, go the pronouncements of the tech world, do what millennia of humans have been unable to: accurately feel someone else's pain. Full story.
Brief Summary: This is a multi-center, prospective, open-label, single-arm, observational, feasibility study. The goal of this study is to determine the feasibility of intra-spinal stimulation with optimal paresthesia coverage therapy for chronic pain relief in [...]
Facing an urgent need for safer and more effective therapies for those suffering from debilitating pain, Saint Louis University researchers are on a mission to find a non-narcotic off-switch for pain. Full story.
Researchers at University of California San Diego School of Medicine have identified specific regions of the brain that drive, influence, and moderate depressive mood and its relationship to perceiving physical pain.Full story.
Despite the availability of therapies, many headache syndromes remain refractory to symptomatic treatment, achieving incomplete resolution of pain, and patients with chronic headaches often pursue nonpharmacologic treatments in hopes of achieving a greater duration of [...]
Patients undergoing the nerve preimplantation procedure had less pain than patients undergoing conventional amputations as measured by best, current, and residual pain scores. The nerve transplant group also experienced less phantom pain. Full story.
Regenerative science has advanced next-generation technologies from the research bench to potential clinical care options. But in the rigorous development of patient therapies, it is critical to validate the safety and efficacy of regenerative solutions. Full [...]
Atogepant, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist for migraine prevention, led to fewer monthly migraine days in episodic monthly migraine patients, results of a phase IIb/III trial showed here. Full story.
© American Academy of Pain Medicine. All Rights Reserved | Privacy Policy | Media Resources | Powered by Insight Marketing Group
American Academy of Pain (AAMP) is a nonprofit, 501(c)(6) tax-exempt organization.
